Cell and gene therapies, which can cost millions of dollars per treatment course, raise serious questions about drug access and equity.

Elevidys, given to patients as a single dose, is approved for use in children ages 4 through 5 years with a confirmed mutation in the DMD gene.

DNA diagnosis a critical first step for children to potentially gain access to trials and eventual treatment.